PortfoliosLab logo
Haemonetics Corporation (HAE)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

US4050241003

CUSIP

405024100

IPO Date

May 9, 1991

Highlights

Market Cap

$3.21B

EPS (TTM)

$2.54

PE Ratio

25.14

PEG Ratio

1.06

Total Revenue (TTM)

$1.03B

Gross Profit (TTM)

$547.80M

EBITDA (TTM)

$215.24M

Year Range

$55.30 - $97.97

Target Price

$96.30

Short %

13.95%

Short Ratio

5.68

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Popular comparisons:
HAE vs. SPYD HAE vs. SPY
Popular comparisons:

Performance

Performance Chart


Loading data...

Returns By Period

Haemonetics Corporation (HAE) returned -12.67% year-to-date (YTD) and -26.36% over the past 12 months. Over the past 10 years, HAE returned 5.30% annually, underperforming the S&P 500 benchmark at 10.45%.


HAE

YTD

-12.67%

1M

11.73%

6M

-22.00%

1Y

-26.36%

5Y*

-8.52%

10Y*

5.30%

^GSPC (Benchmark)

YTD

-3.77%

1M

3.72%

6M

-5.60%

1Y

8.55%

5Y*

14.11%

10Y*

10.45%

*Annualized

Monthly Returns

The table below presents the monthly returns of HAE, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2025-11.57%-5.14%-2.98%-0.83%8.20%-12.67%
2024-10.58%-4.55%16.95%7.73%-8.56%-1.61%8.85%-16.07%6.35%-11.47%22.92%-10.74%-8.69%
20237.57%-8.07%6.40%1.16%1.06%0.64%8.34%-2.72%-0.17%-4.86%-5.12%5.74%8.72%
2022-8.84%19.36%9.55%-19.85%24.85%3.04%6.61%7.97%-1.33%14.75%0.42%-7.81%48.28%
2021-3.76%10.68%-12.25%-39.41%-16.06%18.03%-8.78%3.22%12.49%-2.66%-25.41%3.49%-55.33%
2020-6.54%0.88%-8.00%14.17%-3.60%-18.34%-2.12%2.28%-2.69%15.86%11.63%5.23%3.35%
2019-1.14%-12.17%0.70%-0.23%11.13%24.07%1.45%9.38%-5.53%-4.29%-0.11%-4.73%14.84%
201811.31%9.67%3.19%6.67%15.77%-0.74%8.88%14.34%2.63%-8.82%2.69%-6.74%72.26%
2017-0.85%-6.35%8.68%3.23%-2.63%-3.16%4.15%4.60%4.30%6.00%21.53%0.48%44.48%
2016-1.86%1.39%9.04%-7.29%-13.66%3.54%4.59%22.56%-2.56%-7.73%18.62%1.44%24.69%
20155.83%12.27%1.03%-9.77%1.95%0.10%-3.26%-9.75%-10.50%4.52%-4.56%-0.00%-13.84%
2014-10.06%-3.72%-10.66%-6.84%12.19%3.58%0.82%0.34%-2.16%8.02%-2.09%1.33%-11.18%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of HAE is 16, meaning it’s performing worse than 84% of other stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of HAE is 1616
Overall Rank
The Sharpe Ratio Rank of HAE is 1414
Sharpe Ratio Rank
The Sortino Ratio Rank of HAE is 1313
Sortino Ratio Rank
The Omega Ratio Rank of HAE is 1414
Omega Ratio Rank
The Calmar Ratio Rank of HAE is 2121
Calmar Ratio Rank
The Martin Ratio Rank of HAE is 1919
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Haemonetics Corporation (HAE) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.

Haemonetics Corporation Sharpe ratios as of May 10, 2025 (values are recalculated daily):

  • 1-Year: -0.72
  • 5-Year: -0.21
  • 10-Year: 0.14
  • All Time: 0.22

These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns (including price changes and dividends).

The chart below shows the rolling Sharpe ratio of Haemonetics Corporation compared to the selected benchmark. This view highlights how the investment's risk-adjusted performance has changed over time. For deeper analysis or to customize the calculation, use the Sharpe ratio tool.


Loading data...

Dividends

Dividend History


Haemonetics Corporation doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


Loading data...

Worst Drawdowns

The table below displays the maximum drawdowns of the Haemonetics Corporation. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Haemonetics Corporation was 68.62%, occurring on Jan 27, 2022. The portfolio has not yet recovered.

The current Haemonetics Corporation drawdown is 51.11%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-68.62%Feb 9, 2021245Jan 27, 2022
-60.48%Nov 26, 2001405Jul 7, 2003419Mar 4, 2005824
-53.54%Dec 31, 1993326Apr 17, 19951201Jan 18, 20001527
-46.33%Aug 19, 2019147Mar 18, 2020224Feb 5, 2021371
-42.96%Jul 26, 2013706May 13, 2016349Oct 2, 20171055

Volatility

Volatility Chart

The chart below shows the rolling one-month volatility.


Loading data...

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Haemonetics Corporation over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.


Annual
Quarterly

0.0

Earnings Per Share

The chart presents the Earnings Per Share (EPS) performance of Haemonetics Corporation, comparing actual results with analytics estimates. The company has exceeded analyst expectations for EPS in the past quarter, achieving a 1.7% positive surprise.


0.400.600.801.001.20AprilJulyOctober2021AprilJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober
1.19
1.17
Actual
Estimate

Valuation

The Valuation section provides an overview of how Haemonetics Corporation is priced in the market compared to other companies in the Medical Instruments & Supplies industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


PE Ratio

The chart displays the Price-to-Earnings (P/E) ratio for HAE, comparing it with other companies in the Medical Instruments & Supplies industry. Currently, HAE has a P/E ratio of 25.1. This P/E ratio is considered low compared to industry peers, which may suggest that the stock is undervalued or that the company has weaker growth prospects.

PEG Ratio

The chart shows the Price/Earnings to Growth (PEG) ratio for HAE compared to other companies in the Medical Instruments & Supplies industry. HAE currently has a PEG ratio of 1.1. This PEG ratio is low compared to industry peers, which could indicate the stock is undervalued relative to its expected growth.

PS Ratio

This chart shows the Price-to-Sales (P/S) ratio for HAE relative to other companies in the Medical Instruments & Supplies industry. Currently, HAE has a P/S ratio of 2.3. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.

PB Ratio

The chart illustrates the Price-to-Book (P/B) ratio for HAE in comparison with other companies in the Medical Instruments & Supplies industry. Currently, HAE has a P/B value of 3.5. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items